Magnesium-Zinc-Calcium-Vitamin D Co-supplementation Improves Hormonal Profiles, Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial.
Study Goal
The researchers aimed to assess the effects of magnesium-zinc-calcium-vitamin D co-supplementation on hormonal profiles, inflammation, and oxidative stress in women with PCOS.
Results Summary
The co-supplementation significantly reduced hirsutism, inflammation (C-reactive protein), and oxidative stress (malondialdehyde) while increasing antioxidant capacity, but had no significant effect on free androgen index or other biomarkers.
Population
Women with polycystic ovary syndrome (PCOS)
Effective Dosage
400 mg calcium (plus 100 mg magnesium, 4 mg zinc, and 200 IU vitamin D) twice daily
Duration
12 weeks
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
magnesium-zinc-calcium-vitamin D co-supplementation | decrease | hirsutism | women with PCOS | -2.4 ± 1.2 vs. -0.1 ± 0.4 | resulted in significant reductions | #1 |
magnesium-zinc-calcium-vitamin D co-supplementation | decrease | serum high sensitivity C-reactive protein | women with PCOS | -0.7 ± 0.8 vs. +0.2 ± 1.8 mg/L | resulted in significant reductions | #2 |
magnesium-zinc-calcium-vitamin D co-supplementation | decrease | plasma malondialdehyde | women with PCOS | -0.4 ± 0.3 vs. +0.2 ± 1.0 μmol/L | resulted in significant reductions | #3 |
magnesium-zinc-calcium-vitamin D co-supplementation | increase | plasma total antioxidant capacity concentrations | women with PCOS | +46.6 ± 66.5 vs. -7.7 ± 130.1 mmol/L | resulted in a significant increase | #4 |
magnesium-zinc-calcium-vitamin D co-supplementation | no change | free androgen index | women with PCOS | no significant change | failed to find any significant effect | #5 |
magnesium-zinc-calcium-vitamin D co-supplementation | no change | other biomarkers of inflammation | women with PCOS | no significant change | failed to find any significant effect | #6 |
magnesium-zinc-calcium-vitamin D co-supplementation | no change | other biomarkers of oxidative stress | women with PCOS | no significant change | failed to find any significant effect | #7 |
Data on the effects of magnesium-zinc-calcium-vitamin D co-supplementation on hormonal profiles, biomarkers of inflammation, and oxidative stress among women with polycystic ovary syndrome (PCOS) are scarce. The objective of this study was to assess the effects of magnesium-zinc-calcium-vitamin D co-supplementation on hormonal profiles, biomarkers of inflammation, and oxidative stress in women with PCOS. Sixty PCOS women were randomized into two groups and treated with 100 mg magnesium, 4 mg zinc, 400 mg calcium plus 200 IU vitamin D supplements (n = 30), or placebo (n = 30) twice a day for 12 weeks. Hormonal profiles, biomarkers of inflammation, and oxidative stress were assessed at baseline and at end-of-treatment. After the 12-week intervention, compared with the placebo, magnesium-zinc-calcium-vitamin D co-supplementation resulted in significant reductions in hirsutism (-2.4 ± 1.2 vs. -0.1 ± 0.4, P < 0.001), serum high sensitivity C-reactive protein (-0.7 ± 0.8 vs. +0.2 ± 1.8 mg/L, P < 0.001), and plasma malondialdehyde (-0.4 ± 0.3 vs. +0.2 ± 1.0 μmol/L, P = 0.01), and a significant increase in plasma total antioxidant capacity concentrations (+46.6 ± 66.5 vs. -7.7 ± 130.1 mmol/L, P = 0.04). We failed to find any significant effect of magnesium-zinc-calcium-vitamin D co-supplementation on free androgen index, and other biomarkers of inflammation and oxidative stress. Overall, magnesium-zinc-calcium-vitamin D co-supplementation for 12 weeks among PCOS women had beneficial effects on hormonal profiles, biomarkers of inflammation, and oxidative stress.